secwatch.observer — SEC 8-K summary
======================================

Issuer:     MUSTANG BIO, INC. (MBIO)
CIK:        0001680048
Form:       8-K
Filed at:   2024-01-04T23:59:59+00:00
Accession:  0001558370-24-000056
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Mustang Bio CFIUS review for asset sale to uBrigene enters investigation phase; decision by Feb 12, 2024
--------------------------------------------------------------------------------

- CFIUS began a 45-day investigation after the initial review period expired on Dec 28, 2023 without conclusion.
- CFIUS must complete its investigation no later than February 12, 2024.
- Transaction involves sale of Mustang's Worcester cell processing facility and assets to uBrigene, a Chinese CDMO.
- CFIUS clearance was not a condition to closing the transaction.
- The parties previously withdrew and re-filed their CFIUS notice on Nov 13, 2023 to allow more review time.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1680048/000155837024000056/0001558370-24-000056-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1680048/000155837024000056/tmb-20231228x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-24-000056

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer